BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2026 9:06:33 AM | Browse: 40 | Download: 152
 |
Received |
|
2025-08-06 15:05 |
|
Peer-Review Started |
|
2025-08-06 15:05 |
|
First Decision by Editorial Office Director |
|
2025-09-01 08:36 |
|
Return for Revision |
|
2025-09-01 08:36 |
|
Revised |
|
2025-09-03 18:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-17 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-17 09:30 |
|
Articles in Press |
|
2025-11-17 09:30 |
|
Edit the Manuscript by Language Editor |
|
2025-11-21 00:48 |
|
Typeset the Manuscript |
|
2025-12-09 11:02 |
|
Publish the Manuscript Online |
|
2026-01-20 09:06 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Case Control Study |
| Article Title |
Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dalia E Sherief, Nahla Nosair, Aya Mohammed Abdelhameed, Emad Sadaka, Amira A A Othman and Rasha Elgamal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Amira A A Othman, Chief Physician, MD, PhD, Professor, Department of Internal Medicine, Faculty of Medicine, Suez University, Suez 43511, As Suways, Egypt. amira.othman@med.suezuni.edu.eg |
| Key Words |
Lymphoproliferative neoplasms; Programmed death ligand-1; Programmed death 1; C-X-C motif chemokine receptor 3; Systemic immune-inflammation index; Systemic inflammation response index; Inflammatory biomarkers |
| Core Tip |
This case-control study explores the prognostic value of programmed death ligand-1/programmed death 1 co-expression and C-X-C motif chemokine receptor (CXCR) 3-driven immune signatures in Egyptian patients with lymphoproliferative neoplasms. By integrating flow cytometric analysis with systemic inflammation indices - systemic immune-inflammation index and systemic inflammation response index - the study identifies novel biomarker panels predictive of disease stage, recurrence, and survival. Findings support the use of programmed death ligand-1/CXCR3 and programmed death 1/CXCR3 as clinically relevant tools for risk stratification in resource-limited settings, paving the way for personalized management of lymphoproliferative neoplasms. |
| Publish Date |
2026-01-20 09:06 |
| Citation |
Sherief DE, Nosair N, Abdelhameed AM, Sadaka E, Othman AAA, Elgamal R. Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms. World J Clin Oncol 2026; 17(1): 112801 |
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i1/112801.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v17.i1.112801 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
